Biosimilars Market Worth 23.63 Billion USD by 2023
According to a new market research report "Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 23.63 Billion by 2023 from USD 5.95 Billion in 2018, at a CAGR of 31.7%.
View full press release